

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

MT-4

RRID:CVCL_2632

Type: Cell Line

Proper Citation

ECACC Cat# 08081402, RRID:CVCL_2632

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2632

Proper Citation: ECACC Cat# 08081402, RRID:CVCL_2632

Description: Cell line MT-4 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:1364232](#), [PMID:1765142](#), [PMID:2413616](#), [PMID:8927062](#), [PMID:8957066](#), [PMID:9261343](#), [PMID:29892436](#), [PMID:31554688](#), [PMID:32938764](#)

Comments: Virology: HTLV-1 producing cell line. Expresses Tax. Is permissive for replication of an HIV-1 gp41 mutant lacking the cytoplasmic tail., Characteristics: Was established by co-cultivation of cells from a 50 year old male T-cell leukemia patient with cord leukocytes from a male infant (CelloPub=CLPUB00542)., Population: Japanese., Problematic cell line: Partially contaminated. Two different lots formerly distributed by NIH-ARP; 13 P7 3/9/92 and 150048; were shown not to be authentic MT-4 (PubMed=9261343; PubMed=31554688)..

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: MT-4

Synonyms: MT4

Cross References: BTO:BTO_0003030, CLO:CLO_0007891, CLDB:cl3594, CLDB:cl3599, BEI_Resources:ARP-120, BioSample:SAMN03470803, BioSample:SAMN03472442, ChEMBL-Cells:ChEMBL3308375, ChEMBL-Targets:ChEMBL388, Cosmic:1191697, ECACC:08081402, JCRB:JCRB0135, JCRB:JCRB1216, JCRB:NIHS0145, JCRB:NIHS0529, KCB:KCB 200308YJ,

PubChem_Cell_line:CVCL_2632, Wikidata:Q54906940

ID: CVCL_2632

Vendor: ECACC

Catalog Number: 08081402

Record Creation Time: 20220427T220825+0000

Record Last Update: 20260829T234710+0000

Ratings and Alerts

No rating or validation information has been found for MT-4.

Warning: Problematic cell line: Partially contaminated. Two different lots formerly distributed by NIH-ARP; 13 P7 3/9/92 and 150048; were shown not to be authentic MT-4 (PubMed=9261343; PubMed=31554688).

Virology: HTLV-1 producing cell line. Expresses Tax. Is permissive for replication of an HIV-1 gp41 mutant lacking the cytoplasmic tail., Characteristics: Was established by co-cultivation of cells from a 50 year old male T-cell leukemia patient with cord leukocytes from a male infant (CelloPub=CLPUB00542)., Population: Japanese., Problematic cell line: Partially contaminated. Two different lots formerly distributed by NIH-ARP; 13 P7 3/9/92 and 150048; were shown not to be authentic MT-4 (PubMed=9261343;

PubMed=31554688).. **Warning:** Discontinued: JCRB; NIHS0145

Virology: HTLV-1 producing cell line. Expresses Tax. Is permissive for replication of an HIV-1 gp41 mutant lacking the cytoplasmic tail., Characteristics: Was established by co-cultivation of cells from a 50 year old male T-cell leukemia patient with cord leukocytes from a male infant (CelloPub=CLPUB00542)., Population: Japanese., Problematic cell line: Partially contaminated. Two different lots formerly distributed by NIH-ARP; 13 P7 3/9/92 and 150048; were shown not to be authentic MT-4 (PubMed=9261343;

PubMed=31554688).. **Warning:** Discontinued: JCRB; NIHS0529

Virology: HTLV-1 producing cell line. Expresses Tax. Is permissive for replication of an HIV-1 gp41 mutant lacking the cytoplasmic tail., Characteristics: Was established by co-cultivation of cells from a 50 year old male T-cell leukemia patient with cord leukocytes from a male infant (CelloPub=CLPUB00542)., Population: Japanese., Problematic cell line: Partially contaminated. Two different lots formerly distributed by NIH-ARP; 13 P7 3/9/92 and 150048; were shown not to be authentic MT-4 (PubMed=9261343; PubMed=31554688)..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 324 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang Y, et al. (2025) Mapping HIV-1 RNA structure, homodimers, long-range interactions and persistent domains by HiCapR. *eLife*, 13.

Pfeffer K, et al. (2024) A method for screening functional anti-Treg antibodies using a Treg-like cell line. *Journal of leukocyte biology*.

Carvajal-Barriga EJ, et al. (2023) Sulfated endospermic nanocellulose crystals prevent the transmission of SARS-CoV-2 and HIV-1. *Scientific reports*, 13(1), 6959.

Sales D, et al. (2023) Apigenin improves cytotoxicity of antiretroviral drugs against HTLV-1 infected cells through the modulation of AhR signaling. *NeuroImmune pharmacology and therapeutics*, 2(1), 49.

Boonnate P, et al. (2023) Shikonin Induces ROS-Dependent Apoptosis Via Mitochondria Depolarization and ER Stress in Adult T Cell Leukemia/Lymphoma. *Antioxidants (Basel, Switzerland)*, 12(4).

Sowd GA, et al. (2023) HIV-1 capsid stability enables inositol phosphate-independent infection of target cells and promotes integration into genes. *PLoS pathogens*, 19(6), e1011423.

Polakowski N, et al. (2023) HBZ upregulates myoferlin expression to facilitate HTLV-1 infection. *PLoS pathogens*, 19(2), e1011202.

Pávová M, et al. (2023) Helquat dyes targeting G-quadruplexes as a new class of anti-HIV-1 inhibitors. *Scientific reports*, 13(1), 6096.

Prener L, et al. (2023) Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties. *Journal of medicinal chemistry*, 66(3), 1761.

Zenin V, et al. (2023) Thermostable chaperone-based polypeptide biosynthesis: Enfuvirtide model product quality and protocol-related impurities. *PloS one*, 18(6), e0286752.

Veenhuis RT, et al. (2023) Monocyte-derived macrophages contain persistent latent HIV reservoirs. *Nature microbiology*, 8(5), 833.

Zhao Z, et al. (2023) Anti-HIV Potential of Beesioside I Derivatives as Maturation Inhibitors: Synthesis, 3D-QSAR, Molecular Docking and Molecular Dynamics Simulations. *International journal of molecular sciences*, 24(2).

Martí-Marí O, et al. (2023) Insertion of an Amphipathic Linker in a Tetrapodal Tryptophan Derivative Leads to a Novel and Highly Potent Entry Inhibitor of Enterovirus A71 Clinical Isolates. *International journal of molecular sciences*, 24(4).

Pfeffer K, et al. (2023) Generation and characterization of a monoclonal antibody that binds to Galectin-1. *Protein expression and purification*, 210, 106308.

Zhou Z, et al. (2023) Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-Concept Study. *International journal of*

molecular sciences, 24(2).

Kobayakawa T, et al. (2023) Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins. RSC advances, 13(3), 2156.

Kurahashi Y, et al. (2023) Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL. Blood advances, 7(8), 1545.

Siniavin A, et al. (2022) Anti-HIV Activity of Snake Venom Phospholipase A2s: Updates for New Enzymes and Different Virus Strains. International journal of molecular sciences, 23(3).

Xu W, et al. (2022) A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile. Pharmaceuticals (Basel, Switzerland), 15(4).

Zhong W, et al. (2022) ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1. Blood, 139(7), 1052.